In addition, CD45 and CD19 positive and negative ASC populations were identified in post-mortem CSF of included MS brain donors to investigate whether CD138 and CXCR3 are differently expressed on intrathecal ASCs with a mature and immature phenotype (Fig. 3i). This evidence concerns the gene CD19 and myeloid sarcoma.